Craig-Hallum initiated coverage of LB Pharmaceuticals (LBRX) with a Buy rating and $36 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBRX:
- LB Pharmaceuticals files to sell 4.78M shares of common stock for holders
- LB Pharmaceuticals price target raised to $40 from $35 at Stifel
- LB Pharmaceuticals reports Q4 EPS (45c), consensus (32c)
- LB Pharmaceuticals initiates NOVA-2 trial
- LB Pharmaceuticals Announces Director Zachary Prensky’s Planned Retirement